Dexcom Q4 FY25: where the revenue came from and where it went
The whole income statement of Dexcom for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Oct 1 – Dec 31, 2025
- Reported
- Feb 12, 2026
Revenue$1.26B
+13% year over year
Gross profit$0.79B
63% margin
Operating profit$0.32B
26% margin
Net profit$0.27B
21% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.26 | 100% | +13% |
| US | 0.89 | 71% | +11% |
| Non US | 0.37 | 29% | +18% |
| Cost of revenue | −0.47 | 37% | |
| Gross profit | 0.79 | 63% margin | +4pp |
| R&D | −0.15 | 12% | −1pp |
| SG&A | −0.32 | 25% | −4pp |
| Operating profit | 0.32 | 26% margin | +9pp |
| Other income, net | 0.02 | ||
| Tax | −0.07 | ||
| Net profit | 0.27 | 21% margin | +8pp |
224 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest